Explore the global collaboration landscape for Kv1.3-targeting drugs in 2024, highlighting key clinical players, regional licensing preferences, and strategic partner selection. Learn how to identify ideal license-out opportunities and leverage Unibest's international BD expertise to maximize your drug pipeline's value. Read More

Patent Cliff Looms – Can Kv1.3 Take the Baton for the Next Wave of Drug Licensing?1. Introduction: The Patent Cliff Is Coming, Leaving Market Voids“Patent cliff” refers to the sharp revenue drop pharma companies face when blockbuster drug patents expire, opening the door to generic competition. Read More

Explore the future beyond GLP-1 drugs in diabetes and obesity treatment with amylin analogs. This article dives into the clinical promise, market opportunities, key challenges, and licensing strategies for amylin-based therapies, highlighting why they may redefine the next wave of metabolic medicine. Learn how Unibest supports pharma companies in licensing and accelerating amylin drug development. Read More

This article explores the growing preference for small molecule GLP-1 receptor agonists in developing countries, driven by cost sensitivity, infrastructure limitations, and the need for scalable oral therapies for diabetes and obesity. It examines the economic and clinical advantages of small molecules over biologics, analyzes emerging market dynamics, and outlines how Unibest leverages its sourcing, regulatory, and export expertise to support global access. The piece also reviews current pipeline innovations and the future potential of affordable GLP-1 drugs in underserved regions. Read More

Tirzepatide, a dual GIP/GLP-1 receptor agonist, represents a breakthrough in obesity and type 2 diabetes treatment. This article explores its synergistic mechanism, superior clinical outcomes, and global market potential. It also highlights how Unibest supports global pharma companies with API sourcing, licensing, and regulatory services in the incretin drug space. Read More

IntroductionBreast cancer remains a significant global health challenge, with over 2.3 million new cases diagnosed worldwide in 2022, according to the IARC. The disease burden is disproportionately higher in countries with medium or low levels of the Human Development Index (HDI), where access to in Read More

Alopecia areata (AA) is an autoimmune disorder that goes far beyond mere hair loss. While the physical manifestation of patchy or complete hair loss is its most visible symptom, the impact of AA extends deep into the psychological realm, affecting millions worldwide.Understanding Alopecia AreataAlop Read More

Deucravacitinib has emerged as a groundbreaking treatment for moderate-to-severe plaque psoriasis. As we at Unibest keep up with the current pharamceutical blockbusters, we're excited to explore the potential of this novel drug in the enormous oral systemic psoriasis drug market.A Milestone in Deut Read More

AstraZeneca has announced on June 12, 2024, that Farxiga (dapagliflozin) has been approved by the U.S. Food and Drug Administration (FDA) for improving glycemic control in children aged 10 years and above with type 2 diabetes (T2D). The FDA approval is based on the positive results from the Phase 3 Read More